BioSpace News Archive

Novartis today announced results from an updated invasive disease-free survival (iDFS) analysis of the pivotal Phase III NATALEE trial, with a median follow-up of 33.3 months and following Kisqali® (ribociclib) treatment completion by 78.3% of patients.

The Board of Directors of GE HealthCare Technologies Inc. declared a cash dividend of $0.03 per share of Common Stock for the fourth quarter of 2023 payable on February 15, 2024 to all shareholders of record as of January 16, 2024.

Terran Biosciences, Inc. has received notice of allowance from the United States Patent and Trademark Office (USPTO) for four US patents covering a number of breakthroughs in the psychedelic therapeutic space.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance®) and fulvestrant as a first-line treatment for people with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) today announced the closing of its previously announced underwritten public offering of 13,529,411 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 1,764,705 shares of common stock, at the public offering price of $17.00 per share.

Milestone Scientific Inc., a leading developer of computerized drug delivery instruments that provide painless and precise injections, announced that it has commenced an underwritten public offering of shares of its common stock.

MEDFINITI B.V. and its U.S. subsidiaries, MEDFINITI, Inc. and HemWell MD LLC, are excited to announce the introduction of HemWell, a revolutionary electrosurgical medical device which transforms the approach to hemorrhoid treatment.

TILT Biotherapeutics presented safety and efficacy data from its international Phase I trial in patients with metastatic melanoma, in an oral presentation at the ESMO Immuno-Oncology Congress in Geneva, Switzerland.

IDEAYA Biosciences, Inc. today announced that, on November 30, 2023 , the Compensation Committee of IDEAYA’s Board of Directors granted non-qualified stock options to purchase an aggregate of 40,000 shares of the Company’s common stock to a newly hired employee.

uniQure N.V. today announced the grant of inducement equity awards to newly hired employees.